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ABSTRACT 
Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening 
endoscopy with a platelet count >150x10
9
 cells/L and liver stiffness measurement (LSM) <20 
kPa (Baveno VI criteria). However, the total number of avoided endoscopies using this rule is 
relatively low. We aimed at expanding the Baveno VI criteria and validating them in additional 
cohorts. Patients from the Anticipate cohort (499 patients with cACLD of different etiologies) 
were used to study the performance of different thresholds of platelets and LSM for the 
identification of patients at very low risk (<5%) of having varices needing treatment (VNT). The 
new criteria (Expanded-Baveno VI) were validated in two additional cohorts from London (309 
patients) and Barcelona (117 patients). The performance of the new criteria by etiology of 
cACLD was also assessed. The best new expanded classification rule was platelet count >110 
x10
9
 cells/L and LSM <25 kPa. This was validated in the two additional cohorts. Overall, the 
Expanded-Baveno VI criteria would potentially spare 367 (40%) of endoscopies (21% with 
Baveno-VI criteria) with a risk of missing VNT of 1.6% (95% CI: 0.7-3.5%) in patients within the 
criteria and 0.6% (95% CI: 0.3-1.4%) in the overall population of 925 patients evaluated. The 
Expanded-Baveno VI criteria performed well in cACLD patients with hepatitis C virus, alcoholic 
and nonalcoholic steatohepatitis. Conclusion: The new Expanded-Baveno VI criteria spare 
more endoscopies than the original criteria with a minimal risk of missing VNT in most of the 
main etiologies of cACLD.  
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The progressive introduction of noninvasive diagnostic tools, mainly liver elastography, in the 
management of chronic liver disease, has allowed to identify a population of asymptomatic 
patients with severe fibrosis/compensated cirrhosis, defined by Baveno VI consensus with the 
term “compensated advanced chronic liver disease” (cACLD) (1). These patients are at risk of 
developing any of the two determinants of prognosis in cACLD/compensated cirrhosis: the 
presence of clinically significant portal hypertension and the presence of gastroesophageal 
varices (2,3). However, in these cACLD patients identified in their early phases, the prevalence 
of varices and especially varices needing treatment (VNT, defined as per current Baveno VI 
guidelines as medium-large varices or small with red signs) is very low.  
Based on preliminary information from studies suggesting that liver stiffness measurement 
(LSM) by transient elastography, in combination with other noninvasive parameters, was 
useful for “ruling out” cACLD patients needing screening endoscopy (4–7), the Baveno VI 
recommendations indicated that patients with cACLD a LSM <20 kPa and a platelet count 
>150x10
9
 cells/L  have a very low risk of VNT and consequently, can safely avoid screening 
endoscopy (1). Following that recommendation several studies have now confirmed the 
validity of this risk classification rule (8–11), which allows sparing between 10 to 30% of 
screening endoscopies with a very low risk of missing VNT. However, due to the low 
prevalence of VNT in these cACLD patients (<10%), up to 40% of unneeded endoscopies would 
still be performed (10).  
Possible improvements to the current classification rule have been suggested. One regards the 
use of noninvasive tests (including platelets and LSM) for a continuous risk prediction model to 
individualize the decision to perform endoscopy (Anticipate study) (12). Other studies attempt 
to increase the number of spared endoscopies without rising the risk of VNT missed. Jangouk 
et al. (13) recently reported a 12% increase in spared endoscopies (with no additional VNT 
missed) by expanding the Baveno VI criteria to patients with MELD=6. In addition, a stepwise 
strategy using platelet count >150x10
9
 cells/L and MELD=6 without LSM, substantially 
increased the number of endoscopies avoided, maintaining a very low rate of missing VNT. 
Finally, changes in the platelet count and LSM cut-offs have been also suggested (5–7,14). 
The main aim of the present study was to find and validate a new classification rule for 
avoiding screening endoscopies in cACLD patients maximizing the number of spared 
endoscopies, while keeping very low the risk of missing VNT (<5%). Secondary aims of our 
study were: 1) to analyze the performance of the new classification rule in different etiologies 
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of cACLD, and 2) to externally validate the Baveno VI/MELD=6 and platelet/MELD=6 criteria 
and the performance of the ANTICIPATE continuous model.  
 
METHODS 
Study cohorts 
Data from three different cohorts were retrospectively reviewed and analyzed (Table 1). In the 
Anticipate cohort (12), 542 patients from four centers in Europe (one in France, one in 
Romania, and two in Spain) and one in Canada were evaluated. Patients from the European 
centers were reported, in part, in previous publications; however, there is no data regarding 
the total number of patients evaluated before the inclusion (5,15–17). The patients included in 
that study had cACLD of any etiology defined by LSM ≥10 kPa, Child-Pugh class A and no prior 
liver decompensation. Patients who had paired data on noninvasive tests (blood tests and  
transient elastography) and endoscopy within 3 months were included. In total, 499 patients 
with LSM, endoscopy and platelet count were available for the study.  
The cohort from London (8) was selected from two institutions (Royal Free Hospital and St. 
Mary’s Hospital) and a flow chart of patient inclusion has been already reported. In summary, 
a total of 12331 LSM performed within 2006 and 2015 were evaluated. Of them, 9018 were 
excluded because of LSM <10 kPa, 548 due to inadequate LSM, 403 were repetitions, 81 had 
prior decompensation or splanchnic thrombosis, and 1471 no endoscopy within 12 months of 
elastography. Finally, 310 patients with cACLD were included in this cohort (Table 1). One of 
the patients from this cohort had had a prior splenectomy and therefore, had an unusually 
high platelet count; this patient was not considered for the validation, since Baveno VI criteria 
cannot be applied.  
The third cohort, from Hospital Vall d’Hebron in Barcelona, was composed of 117 cACLD 
patients with hepatitis C chronic infection evaluated before the initiation of direct-acting 
antivirals therapy in 2015. These patients were assessed with blood tests, transient 
elastography and endoscopy during 2014-2015 and they do not overlap with the patients from 
Vall d’Hebron in the Anticipate study. Inclusion criteria were also LSM ≥10 kPa, Child-Pugh 
class A, no prior decompensation of liver disease and endoscopy within 12 months of 
elastography. During this period a total of 608 HCV patients were evaluated for treatment. 
Unrealiable LSM was observed in 47 patients (7.7%) and 300 patients were cACLD patients, 
from which 117 had an endoscopy performed within 12 months of elastography. 
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None of the patients with chronic hepatitis C were on antiviral treatment (interferon-based 
therapy or direct antivirals agents) at the time of inclusion or had previously received it.  
Transient elastography 
The three cohorts used transient elastography by Fibroscan® (Echosens, Paris, France) to 
obtain LSM. The quality criteria used in each cohort for LSM were the criteria recommended at 
the time of the inclusion of the cohorts: 10 valid measurements obtained with a success rate 
≥60% and the interquartile range to median ratio ≤30%. M probe was used in all 
measurements. Data of the number of unreliable/no valid LSM excluded is not available from 
the Anticipate cohort. 
Design of the study  
A sequential analysis plan was designed in order to provide responses for the different aims of 
the study. The different steps were the following: 1) the Anticipate cohort was first used to 
validate the performance of the Baveno VI criteria (1); 2) the same cohort was used to explore 
the expansion of criteria by adding the MELD=6 rule and the platelet/MELD=6 rule (13); 3) the 
Anticipate cohort was also used to study the expansion of Baveno criteria by using previously 
proposed modified LSM and platelet cut-offs (4–7,14) and selecting the best classification rule, 
in terms of endoscopies spared while keeping the risk of missing VNT below 5%; 4) the new 
selected set of criteria (Expanded-Baveno VI) was then validated in the London and Vall 
d’Hebron cohorts; 5) the performance of the Anticipate continuous model for predicting risk of 
VNT was evaluated in the three cohorts by analyzing the rate of endoscopies saved with a 
decision risk  threshold for VNT of 5%; 6) next, the MELD=6 criteria was again added to the 
new Expanded-Baveno VI criteria; 7) an analysis of the performance of the new criteria by 
etiology  was subsequently carried out, and 8) the effect of the variability of platelet count and 
LSM in the performance of the new criteria was finally evaluated. 
Statistical analysis 
Continuous variables were reported as mean ± standard deviation. Qualitative variables were 
compared using Chi-square test. The main outcome of interest for the validation of criteria was 
the prevalence of VNT. VNT were defined according to Baveno VI recommendations as small 
varices (grade 1) with red signs in which beta-blocker therapy is indicated or large varices 
(grade 2 or 3) in which treatment with beta-blockers or band ligation is needed to prevent first 
variceal bleeding (1). The main variable used for the optimization of criteria was the 
percentage of endoscopies spared, while keeping the risk of missed VNT below the pre-defined 
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arbitrary <5% threshold. This threshold was decided by experts in the Baveno VI consensus 
conference who agreed that 5% was a reasonable threshold for missing VNT and later 
endorsed by the American Gastroenterological Association technical review on hepatic 
elastography accepting a 5% false negative rate of missing high risk varices (4,12,18). The 
choice of new cut-off values for the different parameters explored was based on previously 
published reports (4–7,14). The development of the continuous  risk prediction model for VNT 
using LSM and platelets and its corresponding nomogram was extensively reported in the 
Anticipate study (12). In brief, a continuous prediction model for VNT was developed by 
logistic regression using platelet count (capped at 150x10
9
 cells/L) and LSM as covariates. The 
model was internally validated and corrected for optimism with bootstrapping. A nomogram 
for individual risk estimation was built based on the corrected logistic regression model. Data 
was processed using SPSS. For analyses, both SPSS and R statistical platforms were used.  
 
RESULTS 
1) Baveno VI criteria in the Anticipate cohort 
In the Anticipate cohort, 68 of 499 (14%) patients evaluated were within the Baveno VI criteria 
for not performing endoscopy (LSM <20 kPa and platelet count >150x10
9
 cells/L) (Table 2). 
Among these 68 patients, 62 had no varices, 4 (6%) had low risk varices and 2 (3%; 95% CI: 0.8-
10%) presented VNT. This represents that only 2 of 499 patients (0.4%; 95% CI: 0.1-1.4%) had 
VNT missed and were therefore misclassified. This result shows that Baveno VI criteria perform 
well in the Anticipate cohort, but the number of spared endoscopies was low. 
2) Baveno VI/MELD=6 and platelet/MELD=6 rules 
In the Anticipate cohort, 463 patients had data to calculate the MELD score. Among these 
patients, 63/463 (13.6%) met the Baveno VI criteria for avoiding endoscopy with only 2/63 
(3.1%; 95% CI: 0.9-11%) VNT missed. Adding the MELD=6 criteria in those patients who did not 
meet the Baveno VI criteria, the number of spared endoscopies increased by 34/400 (8.5%) 
with no additional VNT missed. Thus, by adding the MELD criteria to the Baveno VI criteria, a 
total of 97/463 (21%) endoscopies could be safely avoided with a low risk of missing VNT 
(2/97- 2%; 95% CI: 0.5-7%), confirming that the number of spared endoscopies could be safely 
increased, with a gain of 7% of endoscopies.  
The other classification rule proposed by Jangouk, et al. (13) was platelet count >150x10
9
 
cells/L or MELD=6 (without the use LSM). In the Anticipate cohort, 161/463 (35%) patients had 
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platelet count >150x10
9
 cells/L, of whom 13 patients (8%) had VNT. Twenty-three patients 
(5%) had platelet count ≤150x10
9
 cells/L and MELD=6 with no patients having VNT. Overall, the 
number of spared endoscopies with these criteria was 184 (39.7%) with 13/184 (7%; 95% CI: 4-
11.7%) VNT missed, indicating that more endoscopies might be saved, but an excessive 
number of VNT (above the pre-defined objective of 5%) would be undetected. 
3) Expanding the Baveno VI criteria: the Expanded-Baveno VI criteria   
Table 2 shows the exploratory data and the performance of a new criteria based on the 
expansion of Baveno VI criteria by increasing the LSM cut-off and/or decreasing platelet count 
in the Anticipate cohort patients. As shown, the combined use of platelet count >110x10
9
 
cells/L and LSM <25 kPa maximized the number of potentially spared endoscopies, while 
keeping the rate of VNT missed below the predefined 5% threshold. We propose the name 
Expanded-Baveno VI criteria for this new classification rule.  
4) Validating the Expanded-Baveno VI criteria (platelet count >110x10
9
 cells/L  + LSM <25 kPa) 
Table 3 shows the performance of the new criteria in all three cohorts. Overall, the risk of 
missing VNT is very low (<2% with a maximum of 3.5% at the upper limit of the 95% confidence 
interval) and, on average, 40% of endoscopies are saved. The clinical characteristics of the 6 
missed patients with VNT are described in supplementary table 1. 
Table 4 depicts the risk distribution of VNT missed in the patients within the Baveno VI criteria 
and the additional patients detected by the new Expanded-Baveno VI criteria (in patients 
beyond the original Baveno VI criteria). Remarkably the risk of missing VNT is the same in both 
sub-groups, suggesting that the new patients selected by the expanded criteria are not 
increasing the risk of missing VNT.   
5) Performance of the Anticipate continuous model 
By using the continuous predictive model of the Anticipate study with a decision threshold of 
5% of risk for VNT in the three cohorts (Table 5), an almost identical observed risk of missing 
VNT was detected with the three classification methods. While the number of saved 
endoscopies was higher using the Anticipate continuous model than with the original Baveno 
VI criteria, the Expanded Baveno-VI criteria maximized the number of saved endoscopies.  
6) Adding the MELD=6 to the Expanded-Baveno VI criteria  
Overall, 883 patients from the three cohorts had information to calculate the MELD score and 
357 (40.4%) were within the new Expanded-Baveno VI criteria. We tested the possibility of 
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applying the MELD=6 criterion trying to identify patients at low risk among those not fulfilling 
the Expanded-Baveno VI criteria (n=526). As shown in table 6, the addition of MELD 6 patients 
(48/526; 9%) to the 357 patients within the Expanded-Baveno VI criteria spared a total of 405 
(45.8%) endoscopies, while the risk of missing VNT remained very low (1.7%; 95% CI: 0.8-
3.5%); the gain in endoscopies saved compared to the new criteria (40.4%) was 5.4%.  
7) Performance of the Expanded-Baveno VI criteria by etiologies  
A subgroup analysis by etiologies of cACLD in all patients from the three cohorts (Table 7) was 
performed. The main etiology was hepatitis C virus (HCV), followed by alcoholic liver disease 
and non-alcoholic fatty liver disease. The new rule seems to perform very well in these three 
main etiologies. The risk of VNT ranged between 0-2.2% and the number of spared 
endoscopies ranged between 38.5% and 49%. For other etiologies (hepatitis B, cholestatic 
diseases, mixed viral and alcohol) sub-group numbers are low to reach robust conclusions.  
8) Effect of the variability of the parameters in the Expanded-Baveno VI criteria  
The variability in LSM and platelet count determinations might have an impact in the proposed 
new criteria, mainly when dealing with values closer to the proposed cut-offs. Thus, a 
sensitivity analysis was conducted to account for the effects of the variability of measurements 
near those thresholds. Evidence from the literature indicates that with experienced personnel, 
LSM variability can reach 20% (19). As for platelet counts, we performed a small evaluation in 
15 HCV patients analyzing and comparing basal counts with 6 and 12 months prior 
determinations. Considering the extreme values, the oscillation was between -11% to 12%.  
Therefore, taking into account the worst case scenario, that is 20% increase in LSM and 10% 
decrease in platelet count to the Expanded-Baveno VI criteria (platelet count >100x10
9
 cells/L 
+ LSM <30 kPa), 11 VNT would be missed in 127 additional patients (11/127; 8.6%-95% CI: 5%-
15%) not receiving endoscopy.  
 
DISCUSSION 
In the present cooperative study, we provide evidence that the original Baveno VI criteria for 
the screening of varices in cACLD patients can be safely expanded (Expanded-Baveno VI 
criteria), increasing the number of endoscopies that can be avoided to almost 50%, while 
keeping the risk of missing VNT very low. In addition, we confirm the validity of the MELD=6 
criteria added to the Baveno VI or Expanded-Baveno VI criteria, although the number of 
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additionally saved endoscopies is low. Finally, the new classification rule seems to be 
applicable to all main etiologies of cACLD. 
The Baveno VI consensus conference introduced some important novelties regarding the 
management of cACLD/compensated cirrhosis patients, partly as a consequence of the 
increasing acceptance of noninvasive testing in chronic liver disease, especially transient 
elastography. The concept of cACLD, the criteria for avoiding screening endoscopy and the 
criteria for selecting patients with clinically significant portal hypertension are all based on  
simple analytical and LSM values (1). The original Baveno VI criteria for the triage of patients 
for screening endoscopy for varices (platelet count >150x10
9
 cells/L + LSM <20 kPa), although 
well validated in subsequent studies (8–11), were also perceived as conservative; the number 
of spared endoscopies was relatively low and about 40% of unneeded endoscopies would be 
performed using  those criteria (10). With the new Expanded-Baveno VI criteria (platelet count 
>110 x10
9
 cells/L + LSM <25 kPa), the number of spared endoscopies could be doubled (from 
21 to 40%) with a minimal risk of missing VNT (<2%). It has to be acknowledged that similar 
classification rules (platelet count >100–120 x10
9
 cells/L and LSM <25 kPa) had been already 
reported by different authors before the Baveno VI consensus conference (5–7) and in a recent 
abstract (14).  
The new classification rule has been developed in the Anticipate cohort and validated in two 
additional cohorts from UK and Spain, including overall over 900 cACLD patients. The two 
validation cohorts presented a lower prevalence (4.5% and 7.7%, respectively) of VNT than the 
Anticipate cohort (13.8%). It could be argued that this would have favored the validation of the 
Expanded-Baveno VI criteria. However, the cACLD population that would mostly benefit from 
avoiding screening endoscopies is probably the cACLD patients with LSM values between 10 
kPa and 25 kPa. It is in the early cACLD population that the risk of having VNT is very low and 
consequently, avoiding endoscopies is critical. Above LSM 25 kPa the risk of having clinically 
significant portal hypertension is more than 90-95% (12) and the presence of VNT rises rapidly. 
With the new Expanded-Baveno VI criteria, three additional patients with VNT were missed 
(Table 4 and supplementary table 1). Two of these patients, both from the London cohort, 
presented one of the classification rule parameters very near the proposed thresholds (platelet 
count 115x10
9
 cells/L and LSM 24.2 kPa). It seems evident that applying the new criteria to 
patients with values approaching the cut-offs may increase the risk of missing VNT. This is also 
evidenced, as discussed in the results, by the effect that the variability, both in LSM (19) and 
platelet counts (20), might have in increasing this risk. Besides measuring liver stiffness with 
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the best possible quality criteria (21), it is advisable, in our opinion, to repeat the LSM and 
platelet count after a short period in patients with values close to the cut-offs to confirm that 
that remain into the low risk group. 
One of the drawbacks of using a single cut-off to separate patients in two groups, is that there 
is always an unwanted loss of information. We might tend to think that the risk of having VNT 
in all the patients within the Expanded-Baveno VI criteria is 1.6%, while it is quite obvious that 
the real risk, better described in the 95% confidence interval, ranges from 0 to at least 3%, 
being higher in patients approaching the cut-offs. For this reason, although we tend to work 
with binary decisions and categorical decision rules are best suited for general 
recommendations, the information of the predicted risk by the continuous model of our prior 
Anticipate study (12) provides useful and complementary information for an individual patient. 
Both approaches point to the same conclusions and could be used in combination in real 
practice, especially in patients with values of platelets and LSM closer to the thresholds of the 
Expanded-Baveno VI criteria.   
Another important information provided by the present study is that the new classification 
rule performs well when analyzed in the main etiologies of cACLD (Table 7). HCV patients were 
clearly overrepresented in the cohort and the Expanded-Baveno VI criteria performed very 
well in this population. However, it is reassuring that in our sample with around 100 patients 
each with cACLD due to alcoholic and nonalcoholic steatohepatitis, the performance of new 
criteria was also very good. In hepatitis B patients, although the number of patients is lower, 
only one VNT was missed. Finally, patients with cholestatic liver diseases constitute a special 
subgroup of patients who might have portal hypertension in early phases of the disease and 
clearly our numbers are too low to draw conclusions. 
Finally, the MELD=6 criteria seemed a promising tool when added to the Baveno VI criteria in 
the initial study (13). Even more attractive it was the proposal of using platelet count plus 
MELD=6, without the need of LSM. From the data of our three cohorts, it is clear that applying 
the MELD=6 criteria to patients beyond the Expanded-Baveno VI criteria can be safely done, 
with an additional gain of spared endoscopies of around 5%. By contrast, we were unable to 
validate the classification rule of MELD=6 without LSM, which would lead to an unacceptable 
high rate of missed VNT. 
Our study has limitations, many of them were already discussed in our previous reports (8,12). 
In short, the main limitations are the retrospective nature of the data, the time frames 
between endoscopy and LSM acquisition (up to 12 months), and the quality control of LSM and 
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endoscopy reporting. Another important limitation is that including LSM in the classification 
criteria is in itself a limitation, because transient elastography is not available in all centers. 
Moreover, we have to keep in mind that LSM cannot be performed in some patients (e.g. 
obese patients, although this can partially be solved with the use of XL probe) and some 
factors such alcohol use, aminotransferases flares or heart congestion can increase liver 
stiffness and therefore provide falsely high LSM values. In these cases an unneeded endoscopy 
might be performed. Finally, since the XL probe has not been used in our study, information 
regarding its utility for the Expanded-Baveno VI criteria cannot be provided. Hence, in real 
world practice, due to all the issues regarding LSM mentioned here, the Baveno VI criteria 
might not be applicable to all patients.  
By contrast, the main strengths of our study are the large number of patients evaluated in 
many centers from different countries, the sequential validation process in external cohorts 
and the similar performance of the new classification rule across different etiologies of cACLD. 
In summary, the present study demonstrates that the Baveno VI criteria for avoiding screening 
endoscopy in cACLD patients can be safely expanded. With the new Expanded-Baveno VI 
criteria (platelet count >110 x10
9
 cells/L + LSM <25 kPa) more endoscopies are spared (100% 
increase from 21 to 40%) with a minimal risk of missing VNT in most of the main etiologies of 
cACLD. The MELD=6 criteria can be safely added to the Expanded-Baveno VI criteria. 
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Table 1. Main characteristics of the three cohorts of the study. 
 Anticipate 
cohort 
N=499 
London 
cohort 
N=309 
Vall d’Hebron 
cohort  
N=117 
Total 
N=925 
Age, years 58.4±10.8 58.1±11.2 66.3±10.3 59.4±11.2 
Male, n (%) 251 (50.3) 208 (67.3) 54 (46) 513 (55.4) 
BMI, kg/m2 27.1±4.8 -* 27.4±3.9 27±5 
HCV patients, n (%) 296 (59.3) 168 (54.4) 117 (100) 581 (62.8) 
Child-Pugh class A, n (%) 499 (100) 274 (88.7) 112 (95.7) 885 (95.7) 
Platelet, x109 cells/L 132±64 157±74 134±61 140±68 
ALT, UI/L 83±60 82±68 97±62 84.7±63 
LSM, kPa 28.1±15.8 23.7±14.5 22.2±10.7 25.9±15.0 
No varices, n (%) 281 (56) 238 (77) 84 (71.8) 603 (65.2) 
Low risk varices, n (%) 149 (30) 57 (18.5) 24 (20.5) 230 (24.9) 
VNT, n (%) 69 (14) 14 (4.5) 9 (7.7) 92 (9.9) 
Continuous data expressed as mean ± standard deviation. HCV: Hepatitis C chronic infection; 
ALT: Alanine-aminotransferase; BMI: Body mass index; LSM: Liver stiffness measurement; VNT: 
Varices needing treatment. *BMI from the London cohort was not available. 
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Table 2. Expanded Baveno VI classification rules to increase the number of spared endoscopies 
without increasing the risk of VNT missed in the Anticipate cohort. 
 
 
Spared endoscopies 
N=499 
VNT missed 
Platelets >150 + LSM <20 kPa 
(Baveno VI) (1)* 
68 (14%) 2/68 (3%) (0.8-10%)
§
 
Platelets >150 + LSM <25 kPa (4-5) 88 (17.5%) 3/88 (3.4%) (1.1-9.5%) 
Platelets >150 + LSM <30 kPa (13) 116 (23%) 6/116 (5%) (2.3-10.8%) 
Platelets >125 + LSM <25 kPa (13) 126 (25%) 3/126 (2.4%) (0.8-6.7%) 
Platelets >120 + LSM <25 kPa (7) 139 (28%) 3/139 (2.2%) (0.7-6%) 
Platelets >110 + LSM <25 kPa 
(Expanded-Baveno VI)  
158 (32%) 3/158 (1.9%) (0.6-5.4%) 
Platelets >100 + LSM <25 kPa (4,6) 182 (36.5%) 9/182 (5%) (2.6-9%) 
VNT: Varices needing treatment; LSM: Liver stiffness measurement. 
*Number of reference. 
§ 
95% confidence interval 
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Table 3. Performance of the Expanded-Baveno VI criteria (platelet count >110 + LSM <25 kPa) 
in all three cohorts. 
Study cohort Spared endoscopies VNT missed/ 
Expanded-Baveno VI
* 
VNT missed/ 
All patients
§ 
Anticipate 158/499 (32%) 3/158 (1.9%) (0.6-5.4%)¥ 3/499 (0.6%) (0.1-1.9%) 
London  161/309 (52%) 3/161 (1.9%) (0.6-5.3%) 3/309 (1%) (0.3-2.8%) 
Vall d’Hebron 48/117 (41%) 0/48 (0%) (0.7-9.2%) 0/117 (0%) (0-3.1%) 
All cohorts 367/925 (40%) 6/367 (1.6%) (0.7-3.5%)  6/925 (0.6%) (0.3-1.4%) 
* 
Risk of missing VNT in patients within the new Expanded-Baveno VI criteria. 
§
 Risk of missing VNT in all patients of the cohort. 
¥ 
95% confidence interval 
VNT: Varices needing treatment 
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Table 4. Comparison of risk of missing the presence of varices needed treatment (VNT) with 
Baveno VI and the additional patients detected by the Expanded-Baveno VI criteria. 
Study cohort VNT missed/ 
Baveno VI
§ 
Additional VNT missed/ 
Expanded-Baveno VI
¥ 
Anticipate, n=158* 2/68 (3%) 1/90 (1.1%) 
London, n=161  1/101 (1%) 2/60 (3.3%) 
Vall dHebron, n=48 0/29 0/19 
All cohorts, n=367 3/198 (1.5%) (0.5-4.3%)# 3/169 (1.7%) (0.4-5.5%) 
* 
Number of patients within the Expanded-Baveno VI criteria.
 
§ 
Risk of missing VNT in patients within the original Baveno VI criteria. 
¥ 
Additional risk of VNT in patients beyond original Baveno VI criteria, but within the new 
Expanded-Baveno VI criteria. 
# 95% confidence interval 
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Table 5. Performance of the Anticipate study continuous model compared to the Baveno VI 
and Expanded-BavenoVI criteria.  
Study 
cohort 
N VNT Anticipate model 
(≤5% VNT)
 §
 
Baveno VI criteria 
LSM<20+pla>150 
Expanded-Baveno VI 
criteria 
LSM<25+pla>110 
EGD 
saved 
VNT missed EGD 
saved 
VNT missed EGD 
saved 
VNT missed 
Anticipate 
499 
69 
(13.8%) 
111 
(22%) 
3/111 (2.7%) 
68 
(14%) 
2/68 (3%) 
158 
(32%) 
3/158 (1.9%) 
London 
309 
14 
(4.5%) 
137 
(44%) 
1/121 (0.8%) 
101 
(32.5%) 
1/101 (1%) 
161 
(52%) 
3/161 (1.8%) 
Vall 
d’Hebron 117 
9 
 (7.7%) 
44 
(38%) 
0/40 
29 
(25%) 
0/29 
48 
(41%) 
0/48 
All 
cohorts 925 
92 
(10%) 
292 
(32%) 
4/292 (1.4%) 
 (0.5-3.4%)
¥
   
198
*
 
(21.5%) 
3/198 (1.5%) 
 (0.5-4.3%) 
367
*
 
(40%) 
6/367 (1.6%) 
 (0.7-3.5%) 
* 
p<0.001, compared with respect to Anticipate model. 
§
 Anticipate study model with a decision threshold of 5% of risk for VNT 
¥
 95% confidence interval 
VNT: Varices needing treatment; LSM: Liver stiffness measurement; EGD: 
Esofagogastroduodenoscopy; pla: platelet count.  
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Table 6. Number of spared endoscopies and varices needing treatment (VNT) missed by 
applying the MELD=6 criterion to those patients who do not fulfill the Expanded-Baveno VI 
criteria. 
Study cohort Spared endoscopies VNT missed 
Anticipate 170/463 (36.7%) 3/170 (1.8%) (0.6-5%)* 
London 179/308 (58.1%) 4/179 (2.2%) (0.9-5.6%) 
Vall d’Hebron 56/112 (50%) 0/56 (0-6.4%) 
All cohorts 405/883 (45.8%) 7/405 (1.7%) (0.8-3.5%) 
* 95% confidence interval 
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Table 7. Performance of the Expanded-Baveno VI criteria by etiologies of cACLD. 
Etiology Spared endoscopies VNT missed/ 
Expanded-Baveno VI* 
VNT missed/ 
All patients§ 
HCV, n=584 236/584 (40%) 3/236 (1.2%) (0.4-3.6%)
¥
 3/584 (0.5%) (0.2-1.5%) 
Alcohol, n=127 49/127 (38.5%) 0/49 (0-7.2%) 0/127 (0-3%)  
NASH, n=90 44/90 (49%) 1/44 (2.2%) (0.4-12%) 1/90 (1.1%) (0.2-6%) 
HBV, n=61 21/61 (34.4%) 1/21 (4.7%) (0.8-22%) 1/61 (1.6%) (0.3-8.7%) 
PBC/PSC, n=20 12/20 (60%) 1/12 (8.3%) (1.5-35%) 1/20 (5%) (0.9-23%) 
HCV/Alcohol, n=19 5/19 (26%) 0/5 0/19 
* 
Risk of missing VNT in patients within the new Expanded-Baveno VI criteria. 
§ 
Risk of missing VNT in all patients of the cohort. 
¥
 95% confidence interval 
VNT: Varices needing treatment; cACLD: Compensated advanced chronic liver disease; HCV: 
Hepatitis C chronic infection; NASH: Non-alcoholic steatohepatitis; HBV: Hepatitis B chronic 
infection; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis.  
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